ePedigree Requirements to Take a Few More Years - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ePedigree Requirements to Take a Few More Years

ePT--the Electronic Newsletter of Pharmaceutical Technology

Sacramento, CA (Oct. 9)—The electronic pedigree mandate for prescription drugs has been delayed again. California Gov. Arnold Schwarzenegger signed legislation that delays ePedigree implementation until 2015.

The deadline was first pushed back last March, from January 2009 to January 2011. Now, manufacturers will have another few years to comply with the new requirement.

Under the act, S.B. 1307, a manufacturer selling drugs in California must have an ePedigree for 50% of the drugs it sells in the state by 2015. As of July 2016, wholesalers or repackagers will be prohibited from selling, trading, or transferring a dangerous drug without a pedigree or from acquiring a dangerous drug without receiving a pedigree; the same rule will go into effect for pharmacies in July 2017. A pharmacy warehouse will not be able to acquire a dangerous drug without receiving a pedigree, as of July 2017.

Industry has been keeping an eye on California’s ePedigree rules as they are likely to impact all US manufacturers and set the stage for a national ePedigree standard. It now looks like companies have more than enough time to prepare.

Read the full legislation here.

Read more about ePedigrees:

ePedigree: Using the Gift of Time Wisely

Epedigree in the Pharmaceutical Supply Chain


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here